ResearchSafe

GHRP-2 vs Tesamorelin + Ipamorelin

A side-by-side research comparison of GHRP-2 and Tesamorelin + Ipamorelin across mechanism, dosing, half-life, benefits, side effects and research status.

Comparison table

AttributeGHRP-2Tesamorelin + Ipamorelin
Full nameGrowth Hormone Releasing Peptide-2 (Pralmorelin)Tesamorelin/Ipamorelin Combination
CategoryGrowth HormoneGrowth Hormone
StatusResearch compoundCompounded combination
MechanismPotent GHSR-1a agonist stimulating GH release and appetite. Also mildly stimulates ACTH/cortisol release.Tesamorelin stimulates GH release by activating GHRH receptors on pituitary somatotrophs. Ipamorelin amplifies the pulse by acting on ghrelin/GHS receptors. Together they produce a synergistic "1+1=3" GH release while maintaining physiological pulsatility.
Molecular weight818 DaBlend
Half-life1-2 hoursTesamorelin: ~26 min; Ipamorelin: ~2 hours. Combined peak GH at 30-60 min post-injection.
BioavailabilityHigh (SubQ)High (subcutaneous)
Typical dose100-300 mcgTesamorelin 1-2 mg + Ipamorelin 200-300 mcg
Frequency2-3x dailyOnce daily (before bed) or twice daily
RouteSubcutaneousSubcutaneous injection

GHRP-2 reported benefits

  • Strongest GH release among GHRPs
  • Appetite stimulation
  • Recovery improvement
  • Enhanced sleep
  • Muscle preservation

Tesamorelin + Ipamorelin reported benefits

  • Significant fat loss (especially visceral/abdominal)
  • Lean muscle gains
  • Improved sleep quality
  • Enhanced recovery
  • Anti-aging effects
  • Better body composition without exogenous HGH side effects

Related comparisons

Research and educational reference only. Not medical advice.